Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Merck & Co. Inc. pages available for free this week:
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Balance Sheet: Assets
- Analysis of Geographic Areas
- Enterprise Value (EV)
- Enterprise Value to EBITDA (EV/EBITDA)
- Enterprise Value to FCFF (EV/FCFF)
- Dividend Discount Model (DDM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Return on Assets (ROA) since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Merck & Co. Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The profitability metrics demonstrate a generally positive trend over the observed period, though with notable fluctuations, particularly in 2023. Initial values show strong profitability, followed by a period of decline, and then a recovery and continued growth through 2025. The most recent quarter (Dec 31, 2025) shows a slight decrease in some metrics compared to the preceding quarter (Sep 30, 2025), but remains at a healthy level overall.
- Gross Profit Margin
- The gross profit margin exhibits a consistent upward trend from 70.72% in March 2022 to 77.18% in September 2025, indicating increasing efficiency in production and cost management. A slight decrease to 74.80% is observed in December 2025, but the margin remains significantly higher than the initial value. This suggests a sustained improvement in the company’s ability to generate profit from its core operations.
- Operating Profit Margin
- The operating profit margin displays significant volatility. It begins at 28.85% in March 2022, peaks at 33.04% in June 2022, then experiences a substantial decline, reaching a low of 3.92% in December 2022. A recovery begins in 2023, with the margin reaching 33.73% in September 2025 before decreasing to 32.64% in December 2025. This fluctuation suggests sensitivity to operating expenses or changes in revenue mix.
- Net Profit Margin
- Similar to the operating profit margin, the net profit margin experiences considerable variation. Starting at 26.27% in March 2022, it declines to 0.61% by December 2022. A strong rebound is then observed, with the margin reaching 29.63% in September 2025, followed by a slight decrease to 28.08% in December 2025. This pattern mirrors the operating profit margin, indicating that changes in operating performance significantly impact net profitability.
- Return on Equity (ROE)
- The return on equity follows a similar trajectory to the profit margins. It decreases from 34.68% in March 2022 to 0.97% in December 2022, then recovers to 36.71% in September 2025, before decreasing to 34.70% in December 2025. This indicates that the company’s ability to generate profits from shareholder investments was initially strong, weakened considerably, and then improved, though with a recent slight decline.
- Return on Assets (ROA)
- The return on assets mirrors the trends observed in other profitability ratios. It declines from 13.29% in March 2022 to 0.34% in December 2022, and then recovers to 14.69% in September 2025, followed by a decrease to 13.34% in December 2025. This suggests that the company’s efficiency in utilizing its assets to generate profits experienced a similar pattern of decline and recovery.
Overall, the period demonstrates a significant recovery in profitability following a challenging period in 2022 and early 2023. While recent quarters show a slight moderation in some metrics, the company maintains a strong profitability position as of December 2025.
Return on Sales
Return on Investment
Gross Profit Margin
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Gross profit | |||||||||||||||||||||
| Sales | |||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||
| Gross profit margin1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Gross Profit Margin, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Gross profit margin = 100
× (Gross profitQ4 2025
+ Gross profitQ3 2025
+ Gross profitQ2 2025
+ Gross profitQ1 2025)
÷ (SalesQ4 2025
+ SalesQ3 2025
+ SalesQ2 2025
+ SalesQ1 2025)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The gross profit margin exhibited a generally increasing trend over the observed period, spanning from March 31, 2022, to December 31, 2025. While fluctuations occurred, the metric demonstrated consistent improvement, particularly from the beginning of 2023 through the third quarter of 2025.
- Initial Period (Mar 31, 2022 – Dec 31, 2022)
- The gross profit margin remained relatively stable, fluctuating between 70.41% and 70.72% during this timeframe. This suggests a consistent cost structure relative to sales revenue in the initial period analyzed.
- Ascending Trend (Mar 31, 2023 – Sep 30, 2025)
- Beginning in March 2023, the gross profit margin began a noticeable upward trajectory. It increased from 72.43% to reach a peak of 77.18% in September 2025. This indicates improving efficiency in production or sourcing, or a shift towards higher-margin products. The increase suggests a strengthening ability to control the cost of goods sold relative to revenue.
- Final Period (Dec 31, 2025)
- A decrease in the gross profit margin was observed in December 2025, falling to 74.80%. This represents a notable decline from the previous quarter’s high of 77.18%. This decrease warrants further investigation to determine the underlying cause, such as increased production costs, pricing pressures, or a change in product mix.
- Overall Trend
- Despite the final quarter’s decline, the overall trend demonstrates a positive development in profitability. The gross profit margin increased from approximately 70.72% in March 2022 to 74.80% in December 2025, representing a net improvement of 4.08 percentage points over the entire period. This suggests a strengthening of the company’s core profitability.
The gross profit figures themselves also generally increased over the period, supporting the margin expansion. However, the December 2025 decrease in gross profit margin, despite a still substantial gross profit value, suggests that sales volume or pricing may have been impacted negatively in that quarter.
Operating Profit Margin
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Operating income (loss) | |||||||||||||||||||||
| Sales | |||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||
| Operating profit margin1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Operating Profit Margin, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Operating profit margin = 100
× (Operating income (loss)Q4 2025
+ Operating income (loss)Q3 2025
+ Operating income (loss)Q2 2025
+ Operating income (loss)Q1 2025)
÷ (SalesQ4 2025
+ SalesQ3 2025
+ SalesQ2 2025
+ SalesQ1 2025)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The operating profit margin exhibited considerable fluctuation throughout the observed period, spanning from March 31, 2022, to December 31, 2025. Initial values demonstrated a strong profitability position, followed by periods of significant volatility and eventual stabilization towards the end of the period.
- Initial Period (Mar 31, 2022 – Dec 31, 2022)
- The operating profit margin began at 28.85% in March 2022, peaking at 33.04% in June 2022 before gradually declining to 30.27% by December 2022. This suggests a period of initially strong, but slowly eroding, operational efficiency.
- Significant Volatility (Mar 31, 2023 – Sep 30, 2023)
- A dramatic shift occurred in the first half of 2023, with the operating profit margin plummeting to 10.34% in June 2023. This was followed by a substantial recovery to 13.08% in September 2023, indicating a significant operational turnaround or the impact of specific, temporary factors. However, this recovery was short-lived, as the margin decreased again to 3.92% by December 2023.
- Recovery and Stabilization (Mar 31, 2024 – Dec 31, 2025)
- Starting in March 2024, the operating profit margin showed a clear upward trend, reaching 24.75% in March 2024 and peaking at 33.73% in September 2025. The margin concluded the period at 32.64% in December 2025. This indicates a sustained improvement in operational performance and a return to a more stable and profitable position. The values in the latter part of the period are generally higher than those observed in the initial period.
- Correlation with Operating Income and Sales
- The fluctuations in the operating profit margin closely mirror the changes in operating income. The substantial decline in the margin during June 2023 and December 2023 corresponds with significant decreases, and even losses, in operating income. Sales figures also appear to influence the margin, though the relationship is not always direct. For example, sales increased from June to September 2023, but the operating profit margin did not increase proportionally.
Overall, the operating profit margin experienced a period of instability before demonstrating a strong recovery and achieving a relatively stable and favorable position by the end of the analyzed timeframe. The volatility observed suggests sensitivity to underlying operational factors and potentially external market conditions.
Net Profit Margin
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Net income (loss) attributable to Merck & Co., Inc. | |||||||||||||||||||||
| Sales | |||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||
| Net profit margin1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Net Profit Margin, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Net profit margin = 100
× (Net income (loss) attributable to Merck & Co., Inc.Q4 2025
+ Net income (loss) attributable to Merck & Co., Inc.Q3 2025
+ Net income (loss) attributable to Merck & Co., Inc.Q2 2025
+ Net income (loss) attributable to Merck & Co., Inc.Q1 2025)
÷ (SalesQ4 2025
+ SalesQ3 2025
+ SalesQ2 2025
+ SalesQ1 2025)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The net profit margin exhibited considerable fluctuation throughout the observed period, spanning from March 31, 2022, to December 31, 2025. Initial values demonstrated a strong profitability position, followed by periods of significant volatility and eventual stabilization towards the end of the analyzed timeframe.
- Initial Period (Mar 31, 2022 – Dec 31, 2022)
- The net profit margin began at 26.27% in March 2022, peaking at 29.00% in June 2022 before gradually declining to 24.49% by December 2022. This suggests a generally healthy profitability level, although a slight downward trend was apparent in the latter half of the year.
- Significant Volatility (Mar 31, 2023 – Dec 31, 2023)
- The period from March 2023 to December 2023 was characterized by substantial swings in net profit margin. A decrease to 22.52% in March 2023 was followed by a dramatic drop to 5.34% in June 2023, indicating a significant decline in profitability. A recovery to 7.77% in September 2023 was short-lived, as the margin plummeted to 0.61% in December 2023. This volatility suggests the presence of substantial, potentially non-recurring, factors impacting earnings during this period.
- Recovery and Stabilization (Mar 31, 2024 – Dec 31, 2025)
- Starting in March 2024, the net profit margin demonstrated a clear recovery. It rose to 3.76% and then experienced a substantial increase to 21.98% in June 2024. This upward momentum continued, reaching 26.68% in December 2024. The margin remained relatively stable in the first half of 2025, fluctuating between 27.27% and 29.63%, before concluding at 28.08% in December 2025. This indicates a return to a more consistent and robust profitability level.
- Overall Trend
- While initial profitability was strong, the period between mid-2023 and the end of the year presented significant challenges. However, the subsequent recovery and stabilization suggest successful mitigation of those challenges and a return to a more sustainable profitability profile. The final values indicate a net profit margin consistently above 25% in the latter quarters, demonstrating a strong financial performance.
Return on Equity (ROE)
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Net income (loss) attributable to Merck & Co., Inc. | |||||||||||||||||||||
| Total Merck & Co., Inc. stockholders’ equity | |||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||
| ROE1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| ROE, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
ROE = 100
× (Net income (loss) attributable to Merck & Co., Inc.Q4 2025
+ Net income (loss) attributable to Merck & Co., Inc.Q3 2025
+ Net income (loss) attributable to Merck & Co., Inc.Q2 2025
+ Net income (loss) attributable to Merck & Co., Inc.Q1 2025)
÷ Total Merck & Co., Inc. stockholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The Return on Equity (ROE) exhibited considerable fluctuation over the observed period, spanning from March 31, 2022, to December 31, 2025. Initial values demonstrated a strong profitability profile, followed by periods of significant volatility and eventual stabilization.
- Initial Period (Mar 31, 2022 – Dec 31, 2022)
- ROE began at 34.68% and peaked at 38.34% in June 2022, indicating a robust return for shareholders. A gradual decline followed, decreasing to 31.57% by the end of 2022. This suggests a potential easing of profitability despite consistently positive net income.
- Volatility and Recovery (Mar 31, 2023 – Dec 31, 2023)
- The first half of 2023 witnessed a dramatic decrease in ROE to 8.04% in June, coinciding with a substantial net loss. A significant recovery occurred in the subsequent quarter, with ROE rising to 11.17% in September. However, this was followed by a sharp decline to 0.97% in December, attributable to another net loss. This period highlights a high degree of sensitivity to net income fluctuations.
- Stabilization and Growth (Mar 31, 2024 – Dec 31, 2025)
- From March 2024 onwards, ROE demonstrated a more stable trend. It increased substantially to 31.52% in June 2024, followed by fluctuations between 27.30% and 36.96% through the end of 2025. The ROE concluded the period at 34.70%, indicating a return to levels observed earlier in the timeframe. This suggests a strengthening of profitability and a reduction in volatility.
- Relationship to Net Income
- A strong correlation exists between ROE and net income. Periods of net loss directly resulted in significantly reduced ROE values, while positive net income generally corresponded with higher ROE figures. The magnitude of ROE changes appears directly proportional to the size of the net income (loss) fluctuations.
- Relationship to Stockholders’ Equity
- Stockholders’ equity generally increased over the period, although a decrease was observed in the first half of 2023. The fluctuations in ROE were not solely driven by changes in net income; shifts in stockholders’ equity also played a role, particularly during periods of significant net loss where equity decreased, exacerbating the decline in ROE.
In summary, the ROE experienced considerable variability, largely influenced by net income performance. While initial periods showed strong returns, volatility emerged in 2023 before stabilizing and demonstrating growth towards the end of the analyzed timeframe. The interplay between net income and stockholders’ equity was crucial in determining the observed ROE trends.
Return on Assets (ROA)
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Net income (loss) attributable to Merck & Co., Inc. | |||||||||||||||||||||
| Total assets | |||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||
| ROA1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| ROA, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
ROA = 100
× (Net income (loss) attributable to Merck & Co., Inc.Q4 2025
+ Net income (loss) attributable to Merck & Co., Inc.Q3 2025
+ Net income (loss) attributable to Merck & Co., Inc.Q2 2025
+ Net income (loss) attributable to Merck & Co., Inc.Q1 2025)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The Return on Assets (ROA) exhibited considerable fluctuation over the observed period, spanning from March 31, 2022, to December 31, 2025. Initial values demonstrated a strong profitability relative to asset base, followed by periods of significant volatility and subsequent recovery.
- Initial Period (Mar 31, 2022 – Dec 31, 2022)
- ROA began at 13.29% in March 2022, increasing to a peak of 15.48% in June 2022. A slight decline followed, reaching 14.25% in September 2022, before settling at 13.30% by the end of the year. This initial phase indicates a consistently healthy return on assets.
- Volatility and Decline (Mar 31, 2023 – Dec 31, 2023)
- The first half of 2023 showed a decrease to 12.09% in March, followed by a substantial negative swing in June, with ROA falling to 2.98%. This was driven by a significant net loss during that quarter. A recovery was observed in September, reaching 4.32%, but this was short-lived as ROA declined sharply to 0.34% by December 2023, again coinciding with a net loss.
- Recovery and Stabilization (Mar 31, 2024 – Dec 31, 2025)
- A notable recovery commenced in early 2024, with ROA increasing to 2.18% in March and then surging to 12.20% in June. This upward trend continued through the remainder of 2024, reaching 14.62% in December. The positive momentum persisted into 2025, with ROA peaking at 15.14% in March, followed by 13.96% in June, 14.69% in September, and concluding at 13.34% in December. This period demonstrates a return to more stable and robust profitability levels.
Throughout the period, fluctuations in net income appear to be the primary driver of changes in ROA. While total assets generally increased over time, the impact of asset growth on ROA was often overshadowed by the variability in net income. The latter half of the observed period suggests a strengthening of the relationship between net income and asset utilization, resulting in improved returns.